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Abstract: Celiac disease (CeD) is a complex immune-mediated disorder that is triggered by dietary gluten
in genetically predisposed individuals. CeD is characterized by inflammation and villous atrophy of the
small intestine, which can lead to gastrointestinal complaints, malnutrition, and malignancies. Currently,
diagnosis of CeD relies on serology (antibodies against transglutaminase and endomysium) and
small-intestinal biopsies. Since small-intestinal biopsies require invasive upper-endoscopy, and serology
cannot predict CeD in an early stage or be used for monitoring disease after initiation of a gluten-free diet,
the search for non-invasive biomarkers is ongoing. Here, we summarize current and up-and-coming
non-invasive biomarkers that may be able to predict, diagnose, and monitor the progression of CeD.
We further discuss how current and emerging techniques, such as (single-cell) transcriptomics and
genomics, can be used to uncover the pathophysiology of CeD and identify non-invasive biomarkers.
Keywords: celiac disease; new biomarkers; diagnosis; follow-up; non-invasive
1. Introduction
Celiac disease (CeD) is a complex immune-mediated disorder triggered by dietary gluten in
genetically predisposed individuals. The estimated worldwide prevalence of CeD is very high
(1–1.5%) [1]. The disease is characterized by inflammation and villous atrophy of the small intestine
that can lead to gastrointestinal complaints, malnutrition, and malignancies. The clinical spectrum
of CeD is, however, broad and can include extra-intestinal symptoms, such as anemia, fatigue and
dermatitis herpetiformis [2]. These factors make CeD complicated to diagnose, and it is estimated
that only 1/3 to 1/9 of all CeD patients are properly diagnosed [3]. Once diagnosed, the only available
treatment for CeD is a strict life-long, gluten-free diet (GFD).
The most recent guidelines recommend starting the diagnostic process for CeD in (1) patients
with symptoms suggestive of CeD, (2) individuals with laboratory abnormalities previously associated
with CeD (e.g., those indicative of malabsorption), or (3) other risk groups such as first-degree
family members of CeD patients, patients with Type I Diabetes Mellitus, and patients with Down
Syndrome [4,5]. Concerning these recent recommendations, serological testing for the presence
of antibodies against gliadin and deamidated gliadin peptide has been replaced by testing for
Immunoglobulin A (IgA) antibodies against tissue transglutaminase (anti-TG2) and endomysium
(anti-EMA), which both display higher sensitivity and specificity [4]. The diagnostic procedure also
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differs between adults and children. Regarding adults, serology is combined with histopathological
evaluation of small-intestinal biopsies [4], and it is important to include a duodenal bulb biopsy to
increase the diagnostic yield [6]. CeD disease status is subsequently scored based on decreased villous
height-to-crypt depth ratio (villous atrophy and crypt hyperplasia) and the influx of intraepithelial
lymphocytes (IELs). The histological classification used for CeD is called the Marsh classification [7].
Regarding children, high antibody titers (anti-TG2 ≥ 10 times the upper limit of normal and positive
anti-EMA in a second blood sample) are sufficient to establish CeD, which makes the diagnosis less
invasive by eliminating the need for duodenal-endoscopy [5]. Children with anti-TG2 levels < 10 times
the upper limit of normal still require a biopsy to confirm CeD.
Since more than 99% of CeD patients are human leukocyte antigen (HLA)-DQ2- or HLA-DQ8-positive,
HLA-genotyping does not have added value for diagnostic purposes, since positive serology correlates
almost perfectly with the presence of these HLA-types [8]. Moreover, these HLA haplotypes also occur in
the general population with a frequency of approximately 40% [9,10]. However, due to its requirement
for the development of CeD, HLA-genotyping can be used to rule out CeD, for example in first-degree
relatives of CeD patients or in individuals who self-diagnose with CeD and start a GFD [4,5].
During this review, we summarize the strategies that are used to identify potential novel molecular
biomarkers for CeD diagnosis and follow-up. To enable an understanding of how diagnostic CeD
biomarkers might be involved in CeD etiology, we first summarize the immunopathology of CeD.
2. CeD Immunopathology
As a complex disease, the pathophysiology of CeD involves a combination of environmental,
genetic, and immunological factors, and possibly also microbial factors (Figure 1).
The most important environmental factor involved in CeD is gluten exposure [11,12]. Glutens are
storage proteins commonly found in grains that are widely used in the Western diet (wheat, barley,
and rye). Due to their high proline content, gluten proteins are inefficiently degraded into peptides in the
small intestine, where they traverse the intestinal barrier and reach the lamina propria by transcellular
or paracellular routes (Figure 1A) [13]. Regarding the lamina propria, gliadin peptides are deamidated
by tissue transglutaminase 2 (TG2) and can be taken up by antigen-presenting cells. Specific deamidated
gliadin molecules have a very high affinity for the CeD-associated HLA-DQ2 and -DQ8 molecules,
which leads to the generation and activation of a pool of gluten-specific CD4+ T cells [14–16]. Activated
gluten-specific T cells then respond and produce the pro-inflammatory cytokines interleukin (IL)-21
and interferon-gamma (IFN-γ) [17]. Furthermore, IL-15, which is a hallmark for CeD, is upregulated
in both the epithelial barrier and the lamina propria. Together, these cytokines orchestrate a cascade
that leads to increased stress in intestinal epithelial cells, migration of CD8+ cells to the epithelial
layer, and activation of B cells. Upon arrival in the epithelial layer, the CD8+ T cells (designated CD8+
intraepithelial lymphocytes (IELs)) are effectively “licensed to kill” epithelial cells, thereby damaging
the villous structure of the small intestine (villous atrophy) [17]. Gluten-specific T cells also promote
the activation of B cells, which develop into plasma cells, thereby producing the auto-antibodies that
are used as the biomarkers in CeD serology tests (Figure 1A) [4,18]. Moreover, a recently proposed
hypothesis suggests that B cells may have an antigen-presenting role in CeD [18,19].
Although gluten peptides play a critical role in CeD immunopathology, not all CeD patients
develop CeD upon their first intake of gluten. It has been postulated that viral (e.g., reovirus and
norovirus [20,21]) and/or fungal infections (Candida [22]) create the environment for an anti-gluten
response to be elicited. Bacterial microbiota also has been implicated in CeD but may act in a different
way than viruses. Duodenal microorganisms have different capacities to degrade gluten. Pseudomonas
aeruginosa, a bacteria enriched in the duodenum of CeD patients for example, produces elastases that
can degrade and modify the gluten to produce gliadin peptides that are highly immunogenic [23],
which may explain how the microbiota can cause imbalance in the immune homeostasis (Figure 1A).
Additionally, it has been shown that some bacterial protein fragments can elicit a stronger activation of
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gluten-specific T cells by binding to HLA-DQ2 [24,25]. However, there is currently no evidence for
which microbes might produce these peptides in CeD patients.
Genetics plays a pivotal role in CeD. The HLA-DQ2 and/or -DQ8 haplotypes are required to
mount the specific response against gliadin peptides. However, ~40% of the Western population
are DQ2/DQ8 carriers, even though only 3% of DQ2/DQ8 carriers develop CeD [10,26,27]. DQ2/DQ8
carriership, thus, is essential for the development of CeD, but carriership is not the cause. Thus far,
genome-wide association studies have identified more than 40 non-HLA risk loci associated with
CeD [28,29]. Together, these loci and the HLA loci explain more than 40% of the heritability of
CeD [30]. Many of the genes in these loci are immune genes [31]. Since most of the non-HLA CeD
single-nucleotide polymorphisms (SNPs) are located in the non-coding genome, they are likely to
contribute to CeD pathology by affecting the expression of genes involved in the biological pathways
that are perturbed in CeD. Although a single SNP might affect only the risk of developing CeD to
a small extent, a combination of multiple SNPs and loci may affect downstream central hub genes that
could implicate novel biomarkers and therapeutic targets [31,32]. Accompanying the recent publication
of data from large case–control genome-wide association studies and population controls, such as the
UK biobank, is the now possible ability to calculate genetic risk scores that combine the additive risk
of multiple CeD risk-SNPs into one score to indicate the risk of developing CeD [10,33,34]. Indeed,
a genetic risk score based on only 46 SNPs differed significantly between CeD patients and controls,
which makes genetic risk scores easier to interpret and implement in future clinical applications than
the whole-genome panels that are used in case–control studies [34].
It is a challenge to clearly identify the individual contributions of environmental, immunological,
and genetic factors to CeD, as none of the currently known factors are sufficient to explain CeD risk
completely. It seems that all these factors are part of an interconnected puzzle that causes loss of
tolerance to gluten and the subsequent clinical manifestations of CeD. Fundamental studies can help
to unravel CeD pathogenesis and identify key players and biomarkers for early detection, monitoring
and control of CeD.
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Figure 1. (A) Schematic representation of t e i unopathology of Celiac Disease (CeD). ietary gluten
is partially degraded by human and microbial proteases. These peptides pass the epithelial layer (IEC:
Intestinal epithelial cell) by paracellular or transcellular transport. Upon entering, tissue transglutaminase
2 (TG2) deamidates the gluten peptides, which are then processed by antigen presenting cells
(APCs) and presented to CD4+ T cells in the context of human leukocyte antigen (HLA)-DQ2 or
HLA-DQ8. After a process of selection, gluten-specific CD4+ T cells propagate and orchestrate the
immune response by producing specific cytokines such as interleukin (IL)-21 and interferon-gamma
(IFN-γ). Combined with IL-15, these cytokines promote the development of B cells into antibody-producing
plasma cells and the activation of intraepithelial lymphocytes (IELs), which acquire cytotoxic properties
to attack intestinal epithelial cells, thereby causing villus atrophy. The immune response in CeD causes
modifications observable in blood such as release of immune- or damage-related markers (highlighted in
red). Figure adapted from Moerkens and Mooiweer et al., [35]. (B) CeD biomarkers currently under study
categorized by different compartments (rows, left) and separated by biotype (columns). Biomarkers
that can be analyzed in easily collected biomaterials rather than invasive biopsies are more desired for
diagnostics (rows, right).
3. Novel Developments in Diagnosis
Rapid screening of high-risk populations is expected to decrease the number of undetected CeD
cases [36]. Recently, effort has been invested in developing point-of-care tests that allow for quick,
non-invasive, cost-effective, user-friendly diagnosis, for instance a test based on detection of IgA
anti-TG2 antibodies in finger prick blood [37,38]. Unfortunately, the clinical studies performed thus
far show that the accuracy and, especially, the sensitivity of these tests need to be optimized before
widespread implementation [4,5,37,39].
Novel developments in endoscopic techniques now can capture the location and extent of villous
atrophy more directly. These approaches include chromoendoscopy (mucosal staining with a specific dye),
confocal endomicroscopy (microscopic visualization during upper-endoscopy) and non-invasive
techniques such as capsule endoscopy, and they have been reviewed extensively elsewhere [40].
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4. Why Do We Need Novel Biomarkers?
To date, CeD diagnosis relies on serology and on biopsies acquired in an invasive manner.
Despite diagnostic advances, there are several reasons to keep searching for additional novel biomarkers
to improve CeD diagnostics and follow-up.
(1) Serological tests can lead to false-negative or false-positive results.
Current serological tests can yield false negatives in IgA-deficient patients. About 2–3% of all
CeD patients display IgA-deficiency, a 10-fold higher incidence than in the general population [41].
False-positive results have been observed in several other (auto-)immune related diseases, such as
primary biliary cholangitis, and in enteric infections [4,42,43]. Moreover, there is a patient group coined
‘potential CeD patients’ who have positive serology but no villous atrophy who, therefore, may not
need to follow a GFD [44,45]. However, the estimated cumulative incidence of children with potential
CeD who develop villous atrophy within the 12-year follow-up after first seropositivity is around
43% [45].
(2) Prevention of severe small-intestinal damage.
Anti-TG2 only appears in circulation after the villous structure of the small intestine is affected.
Novel biomarkers that enable the detection of CeD-onset (for instance in high-risk individuals) could
lead to rapid initiation of a GFD. This would prevent full-blown disease and could be helpful for
distinguishing which potential CeD patients will progress to CeD and which will not.
(3) GFD adherence and response is difficult to monitor.
It is difficult to adhere a strict lifelong GFD. Added to the social consequences of a GFD,
unintentional gluten intake is common when following a GFD due to cross-contact from various sources,
including dietary supplements and even playdough [46]. Currently, GFD adherence is monitored by
dietetic review and serology. However, unintentional gluten intake, and the challenges of monitoring
gluten intake in young children, make it difficult to interpret dietetic reviews and the serological
markers, and even the absence of clinical symptoms, correlate poorly with mucosal healing [47–50].
Regarding cases with persistent symptoms but without elevated anti-TG2, it would be useful to have
additional biomarkers that could exclude dietary lapses as a cause of symptoms. Also, in the case of
intentional gluten intake, for example during puberty, additional biomarkers possibly could reflect
gluten intake with or without mucosal damage without elevated levels of anti-TG2. Novel tools that
allow sensitive and rapid gluten monitoring, ideally by patients themselves, would help to avoid
certain foods and behaviors.
(4) Comorbidities and complications.
Although the most severe complaints may improve within several weeks after starting a GFD,
mucosal recovery is only achieved in about 50% of CeD patients after one year of GFD, even when
a strict diet is followed [48,51]. The persistence of intestinal damage is associated with a higher rate of
CeD-associated complications such as bone abnormalities and malignancies [48,51]. Currently, we have
no biomarkers that predict the onset of co-morbidities in CeD patients, such as dermatitis herpetiformis,
other immune-mediated diseases (e.g., Type I Diabetes or thyroid diseases), or severe complications
such as refractory CeD or enteropathy-associated T cell lymphoma.
(5) Clinical trial evaluation for the development of new treatments.
Assessing villous damage in biopsies is currently the method of choice to evaluate treatment
response to novel drugs for CeD; however, non-invasive markers for mucosal damage or infiltration of
IELs would help in clinical trials to evaluate treatment response [52].
To summarize, the search for novel biomarkers is crucial to improving early diagnosis, decreasing
diagnostic burden, testing treatment efficacy, and improving follow-up and monitoring of CeD
comorbidities after the start of a GFD. Ideally, these biomarkers should be detectable in a material that
can be obtained in a non-invasive or minimally invasive manner, such as blood, feces, or urine.
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5. Non-Invasive and Minimally Invasive Biomarkers
Regarding the next sections, we discuss potential novel non-invasive and minimally invasive
biomarkers for diagnosis and follow-up of CeD and give an overview of how state-of-the-art techniques
could lead to a better understanding of CeD pathology and to novel biomarkers. An overview of the
biomarkers discussed is presented in Figure 1B and Table 1.
5.1. Cytokines, Chemokines and Other Proteins Detectable in Blood
Cytokines and chemokines are key players in the immunopathology of CeD. It is important to
realize that the key driving cytokines or chemokines that are involved in disease initiation, maintenance,
and/or progression may not be detectable in blood. It is possible that these biomarkers are produced in
narrow windows of time or they might be diluted to undetectable levels in circulation. Nevertheless,
some of these proteins are relevant for diagnostics because they reveal specific signature changes in
CeD that can highlight different stages of disease progression.
Basal levels of some cytokines are increased in patients with active CeD compared to patients on
a GFD and using healthy controls. Previous reports describe that the increased serum levels of some
cytokines (such as IL-4, IL-10, IL-1α, IL-1β, IL-8 and IL-21) seen in CeD patients are correlated with
IgA anti-TG2 titers and villous atrophy, making them candidates for diagnostic biomarkers [53,54].
Remarkably, the levels of some cytokines, such as IL-8, remain high for a long time after initiation of
a GFD. This may be linked to the long recovery time of the duodenum and may present a way to detect
CeD in patients already on a GFD.
New techniques to perform targeted high- or medium-throughput proteomics, such as the Olink
platform [55], now make it possible to measure multiple protein markers using a small volume of
sample. Using these techniques, circulating IL-2, IL-8 and IL-17A were detected in blood within
two or three hours after gluten challenge in CeD patients but not in individuals with self-reported
gluten sensitivity [56,57], probably reflecting rapid activation of ‘primed’ gluten-specific T cells upon
antigen exposure. Although the authors found that cytokine response varied broadly among patients,
19 of 26 CeD patients (73%) versus just one of 67 self-reported gluten sensitivity patients (1.5%) were
confirmed as IL-2 responders upon gluten challenge [58]. Interestingly, the patients with the highest
levels of cytokines in the bloodstream also displayed the most severe symptoms [56,57].
To conclude, using the rapid rise of cytokines as a biomarker upon gluten-challenge may reduce
the duration of current diagnostics methods that rely on two- to six-week long gluten challenges for
an accurate result from serology or biopsy tests [4]. Gluten-related cytokine responses also may be
useful clinical biomarkers for assessing patient recovery after CeD-mediated villous atrophy.
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Table 1. Overview of current and future biomarkers for celiac disease (CeD).
Based on Detection of: Functional Group Molecular Biomarker Detectable in: Comments Practical Considerations
DNA HLA-DQ2 or DQ8 HLA-DQ2 or DQ8 Virtually anyhuman tissue
Useful in situations with expected false-negative
serology. Negative HLA-DQ2/DQ8 excludes CeD
reliably without need of gluten challenge. Positive
test requires additional tests.
PCR-based tests available.
Non-HLA loci Risk variants Virtually anyhuman tissue
>40 risk loci identified, mostly in non-coding regions.
Prognostic value of genomic risk scores need to be
evaluated (who will develop CeD and who will not).
Future studies: crucial to find associated genes and
pathways to elucidate pathogenesis, potential new
biomarkers and treatments.
Research in discovery phase.
SNP based tests need to be
developed if genomic risk
score is proven to have
sufficient diagnostic value.
Microbial DNA/RNA Microbiome Not yet available Feces, brushbiopsy
Enrichment for pro-inflammatory bacteria
(Proteobacteria) and depletion of beneficial ones
(Bifidobacterium and Lactobacillus). Studies
necessary on the diagnostic/prognostic value of
individual combined abundance of specific bacteria.
Research in preliminary
discovery phase.
Viral DNA/RNA Virome Not yet available Feces, brushbiopsy, blood
Potential role in triggering the CeD by disturbing the
oral tolerance. Associations found with CeD in
reovirus, rotavirus, enterovirus, adenovirus, hepatitis
C virus, hepatitis B virus, and some strains of
Epstein-Barr virus and Cytomegalovirus. Studies
necessary on the diagnostic/prognostic value of
individual combined abundance of specific viruses.
Research in preliminary
discovery phase.
RNA Bulk mRNA KIAA1109, TAGAP, RGS1,TNFSF14, and SH2B3 Blood
Transcripts overexpressed in RNA form PBMCs of
CeD patients 9 months before diagnosis.





Biomarker for villous-to-crypt ratio in transcriptome
data of biopsies, that eliminates observer variation in
reviewing histological slides. Could help in basis
(large-scale) transcriptome studies where no measured
villous-to-crypt ratio is available and in clinical trials.
Requires small intestinal
biopsy. Suitable to implement
in clinical drug trials.
Small non-coding RNAs MicroRNAs Small intestinalbiopsy, blood
Differences detected between controls and CeD.
Diagnostic and prognostic value to be determined. Research in discovery phase.
Proteins Antibodies anti-TG2 IgA Blood, saliva
Very high sensitivity/specificity for active CeD. Not
reliable if individual is on GFD or has IgA deficiency.
Less useful for follow up.
Currently used as a
serological tool of choice in
clinics. Saliva based and
rapid on site point-of-care
tests are under investigation.
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Table 1. Cont.
Based on Detection of: Functional Group Molecular Biomarker Detectable in: Comments Practical Considerations
anti-TG2 IgG Blood IgG based tests (anti-TG2/anti-DGP) tests of choice incase of IgA-deficiency.




peptides (DGP) IgG Blood See IgG anti-TG2 See IgG anti-TG2.
anti-EMA IgA Blood Used in combination with IgA anti-TG2 to confirmCeD in the non-biopsy approach.
Implemented in clinics. The
indirect immunofluorescence
test is more laborious and
subjective than ELISA based
anti-TG2.








Cytokines and chemokines IL-15 Small intestinalbiopsy
Hallmark of CeD, involved in the T cell response.
Elevated in CeD. Expressed on the surface of cells that
are mainly located in gut.
Requires small intestinal
biopsy.
IL-21 Blood, smallintestinal biopsy
Together with IL-15, involved in the T cell response.









Involved in the T cell response. Distinguishes CeD
cases from self-reported gluten sensitivity patients.
Increased within 2 h after gluten-challenge in CeD.
Elevated serum titers is associated with worse
symptoms. Distinguishes CeD cases from
self-reported gluten sensitivity patients.
Further validation is
necessary before clinical






Involved in the T cell response. Elevated serum basal
levels in CeD. Correlated with anti-TG2 titers.
Increased within 2 h after gluten-challenge. Elevated
serum titers are associated with worse symptoms.




application. Can be used after
a short gluten-challenge test,










application. Requires a short
(hours) gluten-challenge test.
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Table 1. Cont.





Produced by T cells, mainly. Increased within 2 h after




application. Requires a short
(hours) gluten-challenge test.
IL-1a Blood Elevated serum basal levels in CeD. Correlated withanti-TG2 titers.
Further validation is
necessary before clinical
application. Requires a short
(hours) gluten-challenge test.
IL-1b Blood
Elevated serum basal levels in CeD. Correlated with
anti-TG2 titers. Take more than one year of GFD to
diminish to normal levels.
Further validation is
necessary before clinical
application. Potential use to
assess the recovery of villus
atrophy in long-term.
IL-4 Blood Elevated serum basal levels in CeD. Correlated withanti-TG2 titers.
Further validation is
necessary before clinical




Others Blood CCL20, IL-6, CXCL9, IFNγ, IL-10, IL-22, TNFα, CCL2,and amphiregulin. Research in discovery phase.
Peptides Immunogenic glutenpeptides Urine, feces
Indicates presence of (unintended) gluten intake.
Better marker for dietary adherence than IgA
anti-TG2.
Can be detected in urine 3h
after gluten intake, after 3
days in feces. Point-of-care at
home tests are in clinical
trials.
Others I-FABP Blood
Non-invasive marker of villous atrophy. Indicates
damage to small-intestinal enterocytes. Might be
useful to identify patients that do not require
additional biopsies to complement anti-TG2 if
anti-TG2 is increased, but not >10x the upper limit of
normal levels.
Note that elevated I-FABP is
not specific to CeD, but occurs
also in other enteropathies.
Still, as a marker for intestinal
damage is ready to be
validated and implemented
for clinical purposes.
Zonulin Blood Marker for the intestinal barrier integrity.
Detectable by ELISA, but
specificity and intra-
individual fluctuations make
it an unsuitable biomarker.
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Table 1. Cont.
Based on Detection of: Functional Group Molecular Biomarker Detectable in: Comments Practical Considerations




Complex used to identify gluten specific T cells by
using their affinity to gluten epitopes.
Requires FACS, which is labor
intensive, making it a less
attractive biomarker for
clinical applications.
CXCL10, IFN-γ Blood Alternative to HLA-DQ:gluten tetramers to identifygluten specific T cells.
Uses ELISPOT, which is
relatively easy to implement,
but the test is not as specific
as using tetramers.
CD25, CD134 Blood Alternative to HLA-DQ:gluten tetramers to identifygluten specific T cells.
Uses ELISPOT and FACS,
which makes its use more







Marker for subset of gluten specific T cells.
Distinguish CeD on GFD patients. Capable of
indicating a first exposure or a re-exposure to gluten.
Requires FACS, which is labor
intensive, making it a less
attractive biomarker for
clinical applications.
CD8 T cells CD8 Blood Relevant cells for CeD immunopathology, involved inthe cellular mediated immunology.
Can be detected in blood by
FACS after a short gluten
challenge, being suitable
candidates to diagnose CeD





Relevant cells for CeD immunopathology, used in the
biopsy assessment. Cell count is highly increased in
active CeD.
Requires FACS, which is labor
intensive making it a less
attractive biomarker for
clinical application.
Metabolome Lipidome Not yet available Blood
Lipid profile potential prognostic marker: Differences
in lipidome detectable in a high risk cohort between
children that will develop CeD versus those that will
not, before the introduction of gluten. Might be useful
to identify those patients that require intensive follow
up with serology.
Research still in a preliminary,
discovery phase.
Amino acids Citrulline Blood
Non-invasive marker of villous atrophy. Amino acid
specifically present in small-intestinal enterocytes.
Circulating citrulline in blood is a proxy of
small-intestinal enterocyte mass.
Note that elevated citrulline is
not specific to CeD, but




diagnostic yield with I-FABP,
as citrulline might become
a better predictor of
villous atrophy.
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Table 1. Cont.
Based on Detection of: Functional Group Molecular Biomarker Detectable in: Comments Practical Considerations
Drug metabolization Metabolization rate drugsprocessed by CYP3A4 Blood
Non-invasive marker of villous atrophy. Indicates the
expression of CYP3A4 in the small intestine and
therefore a marker of presence of small intestinal
epithelial damage.
Requires the administration
of drugs. Grapefruit juice can
influence the results. Likely
not specific for CeD.
Sugars Large sugars Lactulose/Mannitol ratio Urine Indication of small-intestinal barrier function,different between CeD and controls.
Less attractive biomarker due
to variation in the reliability
of the tests. Still the only
marker for intestinal integrity
that can be measured
non-invasively.
Abbreviations listed in the Table 1: human leukocyte antigen (HLA)); Polymerase chain reaction (PCR); single-nucleotide polymorphisms (SNP); peripheral blood mononuclear cells
(PBMC); gluten-free diet (GFD); tissue transglutaminase (TG); endomysium (EMA); Immunoglobulin (Ig); interleukin (IL); fluorescence-activated cell sorting (FACS); Intestinal fatty-acid
binding protein (I-FABP).
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5.2. Cellular Composition of the Peripheral Blood Mononuclear Cell (PBMC) Fraction and Gene and/or
Protein Expression
Differences in the composition of the peripheral blood mononuclear cell (PBMC) compartment
in blood, or alterations in the expression profiles of these cells, may provide biomarkers for CeD.
Cell types that are highly specific for CeD, such as gluten-specific T cells, but rare or not present in
healthy individuals are of special interest [59].
Gluten-specific T cells can be observed at very low counts in circulation, an issue that can be
overcome by enriching and/or staining them with HLA-DQ:gluten tetramers (a complex of four
subunits of HLA-DQ2 binding to a gluten peptide) and subsequent fluorescence-activated cell sorting
(FACS). Detection of gluten-specific T cells in circulation is a proposed marker for CeD that can detect
CeD after the start of a GFD [59,60].
The HLA-DQ: gluten tetramer method requires staining and sorting the cells (FACS), which is
labor-intensive and difficult to implement on a large scale. Therefore, there have been efforts to find
non-invasive proxies for the number of circulating gluten-specific T cells in CeD using easier and less
expensive methods that can be implemented on a larger scale. This includes the combined measurement
of certain plasma cytokines (like C-X-C Motif Chemokine Ligand 10 (CXCL10)/ IFN-γ) by ELISA
and the detection of the presence of CD25/CD134 positive cells with enzyme-linked immunospot
(ELISPOT) [61].
The detection of surface markers in CeD-associated cell types also can provide valuable
supplementary information. Regarding gluten-specific T cells, Zühlke et al., demonstrated that the
expression of CD38 can distinguish CeD patients on a GFD and indicate a re-exposure to gluten [62].
Phenotyping of surface cell markers of CD8+ and gamma-delta (γδ) T cells is also a good alternative for
diagnosing CeD in individuals who are already on a GFD. López–Palacios et al., showed, after a short
three-day gluten challenge, both cell types co-expressed CD103, integrin β7 and CD38 in 15 out of
15 CeD patients but only in one of 35 controls [61]. Even with the necessity of a laborious technique like
FACS, these biomarkers may have potential for monitoring the efficacy of drugs to treat CeD without
the need for an invasive biopsy.
RNA extracted from peripheral blood cells reflects the cellular composition and state of blood and,
thus, may contain non-invasive markers for CeD diagnosis. Although RNA is sensitive to degradation,
it is easier and cheaper to detect than proteins because this usually requires less input material and
test accuracy does not rely on the specificity of antibodies. Concerning CeD patients, an increase in
Tumor Necrosis Factor Ligand Superfamily 13B (TNFSF13B) messenger RNA (mRNA) levels and
a decrease in TNF Receptor Superfamily Member 9 (TNFRSF9) mRNA levels in whole blood has been
observed [63]. Remarkably, in a longitudinal cohort of high-risk individuals, five genes (KIAA1109,
T Cell Activation RhoGTPase Activating Protein (TAGAP), Regulator of G Protein Signaling 1 (RGS1),
TNFSF14, and SH2B Adaptor Protein 3 (SH2B3)) were overexpressed in PBMCs of CeD patients at
least nine months before CeD diagnosis. Based on expression of these genes, it was possible to classify
CeD cases and controls in 95.5% of patients (n = 22) [64]. These predictive markers may be helpful
for identifying individuals at high risk of CeD earlier than current serological markers, which could
prevent mucosal damage and symptoms because patients could initiate a GFD earlier.
To conclude, detection of CeD-specific cell types in circulation or recognition of specific markers at
protein- and RNA-levels may allow for earlier diagnosis of CeD than current serological methods and
allow for diagnosis without the need for a duodenal biopsy in individuals already following a GFD.
5.3. (Circulating) micro-RNAs
MicroRNAs (miRNAs) have been put forward as disease- or disease stage–specific biomarkers.
MiRNAs are short RNAs (19–24 nucleotides) that play a role in post-transcriptional gene regulation [65].
The miRNA transcriptome can be disturbed in disease-affected tissues, and disease-specific differences
have been measured in extracellular body fluids such as blood, saliva and urine [66–68].
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Several miRNA studies have shown the potential of miRNAs as biomarkers for CeD. Studies on
duodenal biopsies showed that the miRNA profiles of CeD patients differ significantly from those of
controls [69–75]. Only a few studies are available on circulating miRNA profiles in plasma or serum
samples [71,74–76], but there are indications that circulating miRNAs are differentially expressed
between CeD cases and controls. MicroRNA-21 is upregulated in both duodenal biopsies and circulation,
for example [71,74,75].
The function of extracellular miRNAs is under debate. It is feasible that miRNAs in circulation
are a consequence of tissue damage, but it also has been suggested that miRNA-containing vesicles
play a role in the immune synapse and they might act as “micro-hormones” and function elsewhere
in the body [77,78]. This second hypothesis is supported by the findings that miRNAs are selectively
packaged in extracellular vesicles and miRNAs secreted by a donor cell type can be taken up by other
cells and regulate gene-expression [79–81]. Thus, future studies also should assess the advantages of
using miRNAs as potential prognostic markers for CeD.
5.4. Microbiome and Virome
5.4.1. Microbiome
Growing evidence supports the hypothesis that the gut microbiome plays an important role
in CeD pathogenesis. Generally, it has been shown that “beneficial” microbes, such as some
species of Bifidobacterium and Lactobacillus, are decreased in the duodenum of CeD patients,
while pro-inflammatory bacteria, such as Proteobacteria, are more prevalent when compared to healthy
individuals [82]. Olivares et al., showed that children at high risk of developing CeD (HLA-DQ2 carriers
with a first-degree relative affected by CeD) exhibit a different fecal microbiome composition than low risk
(non-HLA-DQ2/DQ8 carriers with a first-degree relative affected by CeD) and healthy individuals [83].
Analysis of stool samples from pre-diagnosis early timepoints in infants who later developed CeD (n = 10)
and children who remained healthy (n = 10) suggested that the HLA-DQ2 haplotypes may alter the early
trajectory of gut microbiota and influence the maturation of the immune system [84].
Although gut microbiome dysbiosis may have potential for prediction of CeD, multiple environmental
factors such as diet, age, sex, and use of antibiotics and other drugs also can affect microbiome composition.
Therefore, potential biomarkers from the microbiome need exploration in larger cohorts.
5.4.2. Virome
Like bacteria, viruses may act as protectors or triggers in CeD development. Potentially protective
viruses include rubella, Epstein–Barr virus, cytomegalovirus, and herpes simplex type 1 virus [85].
Viruses that have been associated negatively with CeD include reovirus, rotavirus, enterovirus,
adenovirus, hepatitis C virus, hepatitis B virus, and some strains of Epstein–Barr virus and
cytomegalovirus [86,87]. Remarkably, exposure to specific viruses, such as reo- and rotaviruses, early in
life is associated with a higher risk for CeD, suggesting that previous infections with this virus may
have triggered CeD onset in some patients [20,88,89].
Viruses may affect mechanisms involved in oral tolerance to dietary antigens. Oral tolerance is
the state in which the immune system accepts the intake of innocuous antigens found in food without
mounting a rejection response [88,90]. Bouziat et al., showed in a mouse model how reoviruses can
induce T helper type 1-associated immunity toward dietary antigens, thereby causing loss of oral
tolerance, in line with observations from experiments with noroviruses [20,21].
To conclude, the exploration of the gut microbiome and the virome in larger and longitudinal
studies may help to identify markers for disease onset and progression of CeD.
5.5. Lipids and Lipid Processing Genes as Markers for CeD
Digestion and absorption of lipids in the small intestine is disturbed in CeD because the surface
area of the small intestine is reduced due to villous atrophy [91]. Studying the circulating lipidome
Int. J. Mol. Sci. 2020, 21, 8528 14 of 25
and other proxies of disturbed lipid uptake and metabolism, therefore, might provide interesting
biomarker candidates for CeD.
Recently, two independent prospective and longitudinal studies in children at high risk for CeD
reported that lipid profiles were significantly different in serum samples of participants who developed
CeD during follow-up compared to the participants who did not develop CeD [92,93]. Changes in
phosphatidylcholines were observed in CeD patients early in life, even before the introduction of
dietary gluten. The authors postulated that these differences are independent of the degree of villous
atrophy and suggested that unknown genetic factors could be the cause. To contrast, a previous
longitudinal study reported that the lipid profile at four months of age did not differ between the
children who did develop CeD and those who did not [94]. Thus, candidate lipid biomarkers need to
be validated on a larger scale before they are clinically applicable.
Considering small-intestinal biopsies of patients with CeD, there is significant deregulation of
key genes or proteins involved in lipid metabolism pathways [91,95–97]. These include Fatty Acid
Binding Protein 2 (FABP2 or I-FABP) and Apolipoprotein A4 (APOA4), which are currently being
studied as potential biomarkers for CeD. When damaged, intracellular I-FABP is released by small
intestinal epithelial cells and can be detected in circulation. Plasma I-FABP has been shown to be
increased in CeD patients compared to controls and correlates with the degree of villous atrophy [98,99].
Moreover, after a two-week gluten challenge in patients with CeD, I-FABP levels increased in 80%
of participants (mean 1.8-fold increase) [100]. Although the exact specificity/sensitivity of I-FABP as
a CeD biomarker fluctuates, in most studies I-FABP has high specificity but lower sensitivity [98,99].
However, because increased I-FABP levels are associated with a range of enteropathies, specificity
is expected to be lower if controls with gastrointestinal complaints other than CeD are included in
specificity studies. Thus far, anti-TG2 serology remains the more reliable diagnostic biomarker in the
studies where I-FABP also is measured [98,99]. Nonetheless, I-FABP might be useful for avoiding
diagnostic biopsies in patients who have elevated anti-TG2 levels but who do not fulfill the criteria for
serological diagnosis (anti-TG2 level > 10 times the upper limit of normal) [98]. Future independent
studies are necessary to validate the added value of I-FABP in CeD diagnostics and to assess whether
it could be used in early prediction or follow-up of CeD.
5.6. Citrulline as a Marker for Mucosal Damage
Plasma citrulline is derived specifically from small-intestinal enterocytes [101]. During a recent
study of 131 adult CeD patients, plasma citrulline levels exhibited a comparable specificity to plasma
I-FABP and a higher sensitivity to detect villous atrophy, making this an interesting biomarker candidate
for monitoring villous atrophy [99].
5.7. CYP3A4 Metabolization as a Marker for Mucosal Damage
Cytochrome P450 3A4 (CYP3A4), which is highly expressed in epithelial cells along the
small-intestinal tract, is a member of the Cytochrome P450 enzyme family that metabolizes a range of
commonly used drugs including simvastatin, a cholesterol synthesis inhibitor. CYP3A4 reduction or
inhibition leads to a reduction in the metabolism of specific CYP3A4 substrates [102,103]. Considering
biopsies of CeD patients, CYP3A4 is decreased [96,97,104,105], leading to a reduction in the
metabolization of substrates [102,103]. Morón et al., showed, after oral simvastatin intake, the maximum
serum level of simvastatin was significantly higher in active CeD (n = 18) compared to healthy controls
(n = 11), and patients on a GFD (n = 25) had simvastatin levels comparable to healthy controls [103].
CYP3A4 metabolizing capacity, therefore, might be an interesting non-invasive proxy for villous
atrophy, although this requires taking serum samples following administration of drugs metabolized
by CYP3A4, making this method less suitable for children.
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5.8. Intestinal Permeability Measurements as Proxy for Intestinal Barrier Function
Intestinal barrier function is impaired in CeD, leading to an increased permeability compared to
controls, and there have been efforts to use these observations as a biomarker for CeD [106].
Zonulin is a protein that regulates tight-junctions and can disturb intestinal barrier function.
It was proposed as a marker for intestinal barrier integrity and is a drug target in clinical trials
for CeD (AT-1001, larazotide acetate) [107–110] (Available online: https://clinicaltrials.gov/ct2/show/
NCT03569007). Some studies suggest that zonulin is indeed higher in serum of patients with CeD
versus controls, but serum values do not change upon start of the GFD, making zonulin unsuitable
for monitoring in follow-up [108,111,112]. The current zonulin detection method also has limitations,
including fluctuations within the same individual in time, and the low specificity for zonulin of some
commercially available ELISA kits [112–114].
Non-invasive tests for intestinal permeability, such as the lactulose–mannitol ratio measured
in urine, are based on the principle that large sugars like lactulose cannot pass the intestinal barrier
under normal conditions but can pass if the integrity of the barrier is affected. The results of these
permeability tests have been shown to differ between CeD patients and controls [111]. However,
the reliability of these tests has been shown to be variable and, therefore, are not recommended as
clinical biomarkers for CeD [4,106,115,116]. Nonetheless, sugar-based permeability tests in urine are
the only completely non-invasive tests available to measure intestinal permeability and, thus, remain
valuable in fundamental studies.
5.9. Gluten Peptides as Biomarkers for GFD Adherence
Immunogenic gluten peptides are interesting markers to measure dietary compliance. ELISA-based
tests that detect immunogenic gluten peptides in feces, serum, or urine are sensitive enough to detect
small quantities of gluten in the diet [117–120]. Immunogenic gluten peptides can be detected frequently
in the stool of patients on a GFD [119]. These studies indicate that unnoticed dietary lapses are common,
even in patients who report strict GFD adherence. Furthermore, 70% of patients positive for gluten
peptides tested negative for anti-TG2 IgA, which suggests that these dietary lapses are not detected
when only measuring anti-TG2 IgA [117,119]. Immunogenic gluten peptides in feces can be detected
approximately three days after a gluten challenge. Immunogenic gluten peptides in urine show up
sooner, but also disappear more quickly, which suggests that measuring gluten in urine might be
more useful for identifying which dietary products contain gluten [118]. Currently, clinical trials
[NCT03462979 clinicaltrials.gov] are testing the use of point-of-care immunogenic gluten peptide tests
at home.
5.10. Antibodies against Tissue Transglutaminases to Detect Skin and Neurological Manifestations of CeD
Serological antibodies against tissue transglutaminase 3 (TG3) and 6 (TG6) have been suggested
as biomarker candidates for extra-intestinal manifestations of CeD. Rapid diagnosis of dermatitis
herpetiformis (by anti-TG3) and of gluten-induced neurological manifestations such as ataxia
(anti-TG6) would be valuable but need further investigation before being implemented in the clinical
setting [4,121–124].
6. Duodenal Biopsies as Source for Novel Biomarkers
Although there is considerable interest in identifying CeD biomarkers that can be found in samples
that can be collected in a non-invasive manner, it is also clear that the disease focus is on the small
intestine. Due to this, fundamental research is focusing on small-intestinal samples of CeD patients
and on the cell types present therein. Novel high-throughput techniques are currently being applied
to uncover pathogenic pathways that are altered in the small intestine of CeD, including (single-cell)
transcriptomics, medium and high-throughput proteomics, and cytometry by time-of-flight (CyTOF).
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It is hoped that these techniques open new avenues that lead to novel biomarkers for CeD diagnostics
and monitoring.
6.1. Transcriptomic Studies: Markers for Small-Intestinal Damage
Transcriptome studies of intestinal biopsies of CeD patients have revealed genes and pathways
that are altered by disease which, therefore, have potential as markers for small intestinal damage
and function.
The transcriptome of the small-intestine can be used as a marker for the villous-to-crypt-ratio
measured in histopathological slides [125,126]. The ratio of two genes, APOA4:Ki67, correlates well
with the degree of villous atrophy, for example. APOA4 is a lipid-processing gene highly expressed in
intestinal villi, whereas Ki67 is a broadly used cellular proliferation marker expressed in the intestinal
crypts [69,95,104,127]. Measuring these genes in biopsies could help to reduce observer variation in
reviewing histological slides and allow assessment of villous atrophy in (public) RNA-sequencing data
for which the villous-to-crypt ratio is not available.
Added to the examples discussed above of how deregulated pathways in CeD, such as
drug-metabolization, have led to biomarkers for CeD, there are other pathways/genes identified
by transcriptome studies that might be worth exploring as non-invasive markers. Lactase (LCT)
has a lower expression in CeD biopsies [95,97,104]. LCT encodes for the enzyme that breaks down
lactose, and lactase activity can be measured reliably by a non-invasive hydrogen breath test [128].
Lactose malabsorption is common in CeD, and there are indications that this phenotype improves
upon adopting a GFD [128,129]. Furthermore, among the upregulated immune-related genes in
CeD biopsies, some can be measured in feces. These include the gene S100A9, which forms the
heterodimer calprotectin, and the antimicrobial peptide lipocalin (LCN2, also known as NGAL
(Neutrophil Gelatinase-Associated Lipocalin)), both of which are used as fecal biomarkers for disease
activity in inflammatory bowel disease [104,116,130–132]. Deregulation of these genes is not specific
for CeD but might be a potential proxy for small-intestine health, either individually or combined with
other markers for mucosal damage.
6.2. Single Cells to Multi-Dimensions
The proteome or transcriptome profile of bulk samples, such as small-intestine biopsies or blood
of CeD patients, is mainly driven by the cell type–composition of each tissue. However, the more
abundant cells may overshadow the expression of rare cells present in tissues. Therefore, the use of
high-throughput techniques, especially those that allow the characterization of single cells, is essential
in the study of complex diseases.
Classically, FACS has been used to study cell surface markers and internal proteins in single cells.
To date, FACS allows the analysis of up to 20 proteins at the same time in millions of cells. Recently,
CyTOF has emerged as a technology that combines the principle of FACS and mass spectrometry.
CyTOF allows the study of around 40 surface markers in millions of cells [133]. Recently, van Unen et al.,
applied this technology to gut biopsies and PBMCs of CeD patients, refractory CeD patients, and Crohn’s
disease patients and pinpointed differences between the three patient groups [134].
Another emerging approach is single-cell RNA sequencing (scRNAseq) [135], which characterizes
the transcriptome at a single-cell level. While the number of cells that can be analyzed simultaneously
by scRNAseq is low compared to FACS and CyTOF (thousands to millions, respectively), the number
of markers that can be analyzed increases to thousands of genes. ScRNAseq also does not require
prior knowledge about which markers to use. Considering the context of CeD, Atlasy et al., identified
an Natural Killer T–like cell subset that was absent in the duodenum from CeD patients and CeD-specific
transcriptome changes in T cells, myeloid cells, and mast cells [136].
ScRNAseq also can be combined with methods that detect other layers of data in the same cell.
Some examples of multilayer techniques include the characterization of cell surface markers
(CITE-seq [137]), whole genome screening of open (active) chromatin (single-cell RNA/ATAC-seq [138]),
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actual position in the tissue by spatial transcriptome reconstruction, or mass cytometry imaging [139–141].
All these advances hold promise as the foundation for a multidimensional understanding of complex
diseases. Henceforth, combining these high-throughput multi-omics studies with new model systems
for CeD, like organ-on-chip technology [35], can help identify potential biomarkers in the pathogenesis
of CeD.
7. Conclusions and Future Perspectives
During this review we have discussed non-invasive biomarker candidates that may complement
current diagnostics and monitoring of CeD. Some of these markers are already being validated and/or
implemented in the clinic. We also briefly highlighted how modern high-throughput techniques can
help find new targets for diagnostics, monitoring, and drug development.
The current serological markers, TG2- and EMA-antibodies, are the cornerstone of the diagnosis
due to their high specificity/sensitivity. However, simultaneously measuring additional markers for
intestinal damage or function, such as citrulline or I-FABP, could identify cases with villous damage in
future, thereby reducing or replacing the need for invasive biopsies in cases with borderline serology.
Even if the individual biomarker candidates discussed here turn out to be more general markers of
intestinal damage or inflammation, and nonspecific for CeD, efforts should be made to assess the
diagnostic value of using combinations of these biomarkers for CeD.
Currently, there are no biomarkers to predict who will develop CeD. Genetics may provide part
of the key. Genetic screening already has the potential to identify those individuals at highest risk for
CeD, and new algorithms are being tested to increase the predictive power of genetic risk scores [34].
Future studies also should focus on whether genetic risk scores have added value over the use of
serology alone, and whether genetic risk scoring would help to identify individuals who would benefit
from serological screening for CeD at specific points in their lives. Many of the other markers described
here such as the lipid profile and changes in circulating cell types or gene/protein expression, are also
worth investigating as predictive tools for CeD.
Previously mentioned, one of the disadvantages of current diagnostics based on antibodies is
that they cannot be used to diagnose patients already following a GFD. The option to establish the
diagnosis in patients who are on a GFD after a single dose of gluten by measuring specific circulating
cytokines is worth exploring because it eliminates the need for a longer gluten challenge, which may
cause intestinal damage and symptoms. Measuring cytokines also could be a quick assay to assess the
response to a gluten challenge after administration of adjuvant treatments in clinical trials. This would
have huge benefits for assessing drug efficacy in CeD, since invasive duodenal biopsies would not be
required to assess how patients are responding to a gluten challenge.
Hereafter, even dietary lapses and unintentional exposures might be detectable by measuring
gluten peptides in urine, as studies so far have shown that these are quicker and more sensitive markers
than anti-TG2.
Next steps would be to further explore the heterogeneity of CeD to identify markers that could
help to predict who will develop complications associated with CeD or other immune-mediated
diseases. We would like to emphasize that fundamental studies investigating the pathogenesis of CeD
are essential in working toward more personalized diagnostics, monitoring, and treatment of CeD.
Results of current and future fundamental research have yielded and will yield interesting non-invasive
markers for CeD.
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